AMORFIX FEATURED ON TODAY IN AMERICA WITH TERRY BRADSHAW

TSX: AMF

TORONTO, June 23, 2011 /CNW/ - Amorfix Life Sciences Ltd., a product development company focused on diagnostics and therapeutics for misfolded protein diseases, announced today that the company is currently being featured on the television program Today in America with Terry Bradshaw.  The program describes the Company's efforts to develop a new test for the diagnosis of Alzheimer's disease.  The program will be aired over the next few weeks in multiple regions throughout the United States and has been placed on the Corporate website available for public viewing (www.amorfix.com).

"The program highlights the pioneering work that Amorfix has performed in the area of new diagnostics for the accurate diagnosis of Alzheimer's disease", said Dr. Robert Gundel, Amorfix Chief Executive Officer.  Our technology enables the identification and subsequent measurement of misfolded proteins that are present in an excess of normally folded proteins.  In the case of Alzheimer's disease, we have demonstrated the ability to measure aggregated Abeta amyloid in the cerebrospinal fluid of Alzheimer's patients.  Abeta amyloid is a misfolded protein which is known to be the building block of plaque formation in the brains of Alzheimer's disease patients and is a known biomarker for the disease.  This work represents an important step in the direction of having a new diagnostic tool available for the early and accurate diagnosis of Alzheimer's disease and the potential to identify patients with mild cognitive impairment who may progress to Alzheimer's disease.  We believe that this is the most important area for a new diagnostic since there is currently no way to identify patients showing initial signs of dementia who will progress into Alzheimer's disease."

"Today there are more than 5 million people with Alzheimer's disease in North America and the numbers are expected to grow at an alarming rate over the next 20 to 30 years making this one of the most significant healthcare issues" said Dr. Neil Cashman, Amorfix Chief Scientific Officer.  The development of a new diagnostic that can detect the onset of Alzheimer's disease early will be an important part of our success in getting new treatments on the market as soon as possible."

Alzheimer's disease is a chronic neurodegenerative disease characterized in part by memory loss, confusion, disorientation, and mood changes. Currently, the only definitive diagnostic for Alzheimer's disease is post-mortem examination of brain tissue to detect neurofibrillary tangles and deposits of aggregated misfolded Abeta amyloid in plaques in and around neural tissue.

About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's Disease (AD), cancers, and ALS. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection™ technology enables it to specifically identify very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a human screening test for AD. For more information about Amorfix, visit www.amorfix.com.

Forward-Looking Information
This press release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Amorfix Life Sciences Ltd.

For further information:

Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
bob.gundel@amorfix.com
    Janet Clennett
Acting Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899
janet.clennett@amorfix.com

 

Profil de l'entreprise

Amorfix Life Sciences Ltd.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.